Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6646143 | 0.83 | LTA4H (0.51) | MAPTALDH1A1LMNAKDM4E | |
| SCHEMBL17298803 | 0.82 | HSPB1 (0.42) | HSPB1MEN1KMT2AGAAL3MBTL1 | |
| SCHEMBL6920000 | 0.79 | MGLL (0.41) | HSPB1MEN1KMT2AGAAMAPT | |
| SCHEMBL15243969 | 0.79 | MAPT (0.46) | IDO1MEN1KMT2AGAAMAPT | |
| SCHEMBL6644748 | 0.79 | SMN1; SMN2 (0.52) | MEN1KMT2AGAAMAPTALDH1A1 | |
| SCHEMBL6919997 | 0.77 | CYP1A2 (0.48) | MEN1KMT2AGAAMAPTALDH1A1 | |
| SCHEMBL6644390 | 0.77 | IDO1 (0.47) | IDO1MEN1KMT2AGAAMAPT | |
| SCHEMBL17672793 | 0.76 | HSPB1 (0.51) | HSPB1MEN1KMT2AGAAL3MBTL1 | |
| SCHEMBL3333575 | 0.75 | MAPT (0.58) | HSPB1MEN1KMT2AGAAL3MBTL1 | |
| SCHEMBL1641137 | 0.75 | LTA4H (0.61) | HSPB1MEN1KMT2AMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039795-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | IDO1 699/4885HSPB1 302/4885MEN1 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.